New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SCCO;IP;MOS;ADM;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
09:44 EDTMOSOTR Global upgrades Nitrogen and Potash/Phosphate
Subscribe for More Information
December 17, 2014
15:09 EDTNVSNovartis unit gets FDA approval for swimmer’s ear treatment
Subscribe for More Information
12:10 EDTADM, MOSMosaic acquisition of Archer Daniels fertilizer unit to spur growth in Brazil
The Mosaic Company (MOS) announced that it has completed the previously announced acquisition of Archer Daniels Midland's (ADM) fertilizer distribution business in Brazil and Paraguay for $350M. The assets purchased include $150M in working capital. The acquisition is expected to significantly accelerate Mosaic's growth plans in Brazil as well as replace a substantial amount of planned internal investment in that country. Mosaic's distribution capacity in the region is expected to increase from approximately four million tonnes per year to 6M tonnes. As a result of the acquisition, Mosaic intends to manage and report a new international distribution segment beginning in the first quarter of 2015.
07:29 EDTNVSFDA PDUFA Date for Novartis Bexsero is December 17, 2014
Subscribe for More Information
December 16, 2014
08:47 EDTNVSHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
07:06 EDTNVSBioLineRx and Novartis enter into strategic collaboration agreement
Subscribe for More Information
06:24 EDTADMArcher Daniels price target raised to $57 from $52 at Citigroup
Citigroup raised its price target for Archer Daniels shares to $57 from $52 following the company's analyst day and sale of its underperforming cocoa business. Citi sees continued momentum in ADM's core processing and transportation businesses and keeps a Buy rating on the stock.
05:48 EDTNVSNovartis gains FDA approval for Signifor LAR
Subscribe for More Information
December 15, 2014
18:30 EDTADMArcher Daniels to sell global cocoa business to Olam for $1.3B
Subscribe for More Information
18:08 EDTADMOlam to acquire Archer Daniels cocoa business for $1.3B, Bloomberg reports
December 12, 2014
08:36 EDTNVSNovartis reports BOLERO-1 trial did not meet primary objective
Subscribe for More Information
05:31 EDTNVSNovartis reports Cosentyx 'superior' in head-to-head psoriasis study
Subscribe for More Information
December 11, 2014
08:16 EDTMOSBHP sees potash as focus for growth in China, WSJ reports
Mining giant BHP Billiton said it is focusing on potash as an area of strategic growth in China, with Mike Henry, a president for BHP saying potash "can be our fifth pillar,” adding to the four key markets of iron ore, oil and natural gas, copper and coal that the company had identified previously, reported The Wall Street Journal. Other publicly traded companies in the potash space include Agrium (AGU), Intrepid Potash (IPI), Mosaic (MOS), Potash (POT). Reference Link
December 10, 2014
12:04 EDTADM, MOSUSDA lowers 2014/15 soybean ending stock forecast
Subscribe for More Information
07:56 EDTMOSUBS to hold a conference
Agriculture Investor Day is being held in Chicago on December 10.
07:40 EDTIPBofA/Merrill to hold a conference
2014 U.S. Basic Materials Conference is being held in Boston on December 10-11.
December 8, 2014
13:07 EDTNVSNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
13:05 EDTNVSNovartis reports six-year results from Phase III ENESTnd study
Subscribe for More Information
11:30 EDTNVSLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use